title: Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
abstract: Sialic acid is a negatively charged sugar associated with the protein and lipid portions of lipoproteins. Sialic acid has been hypothesised to play an anti-atherogenic role in lipoprotein metabolism through the electrostatic inhibition of lipoprotein interactions with chondroitin-6-sulphate-rich arterial proteoglycans (APG). We conducted a series of studies using native and modified lipoproteins (VLDL1 Sf 60-400, VLDL2 Sf 20-60, IDL1 Sf 16-20, IDL2 Sf 12-16, LDL(A) Sf 8-12, and LDL(B) Sf0-8) that vary in their sialic acid content to examine the relationship between lipoprotein sialic acid content and its interaction with APG. Lipoprotein sialic acid was greatest in VLDL1 and decreased progressively with particle density until the IDL2 fraction (VLDL1 > VLDL2 > IDL1 > IDL2 = LDL(A) = LDL(B)). The pattern of reactivity of each fraction with APG was different from the pattern observed for lipoprotein sialic acid content (IDL2 > LDL(A) > LDL(B) > IDL1 > VLDL2 > VLDL1). Levels of sialic acid were lower in subjects with CHD as compared to control subjects but the presence of CHD had no effect on lipoprotein-APG complex formation when sex and plasma triglyceride levels were taken into account. There was also no significant relationship between the lipoprotein sialic acid content and the reactivity with APG within each lipoprotein fraction. Treatment of hypertriglyceridaemic subjects with ciprofibrate decreased lipoprotein-APG complex formation in all lipoprotein fractions. This was associated with a decrease in the total sialic acid content of apo B100-containing lipoproteins suggesting that the total sialic acid content of apo B100-containing lipoproteins has no influence on lipoprotein-APG complex formation. We next conducted in vitro experiments to manipulate LDL sialic acid content. Enzymatic removal of sialic acid from LDL with neuraminidase resulted in an increase in LDL-APG complex formation. This was accompanied by an increase in the exposure of free amino groups on LDL possibly due to disruption of interactions between free amino groups and sialic acid-containing components on LDL. Increasing LDL sialic acid content through incubation with ganglioside resulted in a decrease in lipoprotein-APG complex formation without any changes in the exposure of free amino groups on LDL. We conclude that total sialic acid content of lipoproteins is not a major determinant of their binding to APG. However, specific sialic acid-containing components on lipoproteins can affect their interaction with APG.
authors.affiliation: Department of Pathological Biochemistry, Glasgow Royal Infirmary, Scotland, UK.
authors.forename: J S
authors.initials: JS
authors.lastname: Millar
authors.forename: V
authors.initials: V
authors.lastname: Anber
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
authors.forename: C J
authors.initials: CJ
authors.lastname: Packard
mesh_terms: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy; D005260:Female; D058607:Fibric Acids; D005679:G(M3) Ganglioside / Q000494:pharmacology; D006028:Glycosphingolipids / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008297:Male; D019158:N-Acetylneuraminic Acid / Q000378:metabolism*; D009439:Neuraminidase / Q000494:pharmacology
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D011508:Chondroitin Sulfate Proteoglycans; D058607:Fibric Acids; D005679:G(M3) Ganglioside; D006028:Glycosphingolipids; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D002995:Clofibric Acid; D002784:Cholesterol; D009439:Neuraminidase; C019304:ciprofibrate; D019158:N-Acetylneuraminic Acid